Regulations for the Submission and Presentation of Scientific Papers

Submission and Presentation of Scientific Papers

Purpose

These Regulations establish the conditions for the submission, evaluation, acceptance, presentation, and awarding of scientific papers at the SLAC Congress and IAC Tutorial 2027. Submission implies that all authors have read, understood, and fully agreed to the rules set forth herein.

1 - Event and Organization

1.1 - The SLAC Congress and IAC Tutorial 2027 will take place from April 20 to 23, 2027, in Florianópolis, Santa Catarina, Brazil.

1.2 - The scientific process will be overseen by the Scientific Committee and the Scientific Paper Review Committee, hereinafter jointly referred to as the Scientific Committees.

1.3 - The Scientific Committees may make decisions regarding matters not covered by these Regulations, while ensuring impartiality, confidentiality of the review process, and equal treatment of all participants.

2 - Schedule

2.1 - All times will follow Brasília official time (BRT). Authors are encouraged to complete their submissions well in advance, as last-minute technical issues will not automatically result in an extension of the deadline.

2.2 - Any changes to the schedule will be announced through the Congress's official communication channels.

Stage

Date / Period

Submission period opens

September 20, 2026

Submission deadline

January 31, 2027

Abstract review

February 1–28, 2027

Announcement of results

March 5, 2027

Publication of presentation guidelines

March 5, 2027

Deadline for the presenting author to complete registration

April 10, 2027

Congress dates

April 20–23, 2027

3 - Eligibility and Author Responsibility

3.1 - Professionals, researchers, faculty members, medical residents, graduate students, and undergraduate students affiliated with cytopathology or related fields may submit papers.

3.2 - Submissions may be made after completing a preliminary registration in the system. Payment of the Congress registration fee is not required to submit an abstract.

3.3 - The presenting author of an accepted paper must be fully registered for the Congress by April 10, 2027. Failure to complete registration may result in the paper being removed from the scientific program, as is customary at other Pathology congresses.

3.4 - The submitting author declares that they have obtained the consent of all co-authors regarding authorship, content, presentation, and publication of the abstract in the Congress materials.

3.5 - The same content may not be submitted more than once, even if the title, category, or author order is changed. If duplicate submissions are identified, only the most recently submitted version received before the deadline will be retained.

3.6 - Authors are responsible for the scientific accuracy, integrity, originality, authorship, and compliance with the ethical standards applicable to their work.

4 - Categories and Presentation Formats

4.1 - Authors must select a category at the time of submission. The final presentation format will be determined by the Scientific Committees based on the quality and ranking of the paper, as well as the availability of space in the scientific program.

4.2 - Indicating a preference for an oral or poster presentation does not bind the Scientific Committees to that choice.

Submission Category

Scope

Possible Presentation Format

Scientific Communication

Original research, case series, or other scientific studies with completed results.

Oral or poster

Case Report

A relevant case with scientific, diagnostic, or educational contributions.

Poster; oral presentation in exceptional cases

Scientific Communication

Scope

Original research, case series, or other scientific studies with completed results.

Possible Presentation Format

Oral or poster

Case Report

Scope

A relevant case with scientific, diagnostic, or educational contributions.

Possible Presentation Format

Poster; oral presentation in exceptional cases

5 - Language, Format, and Word Limit

5.1 - Abstracts may be submitted in Portuguese, Spanish, or English.

5.2 - Abstracts must not exceed 500 words, regardless of category.

5.3 - The title must be descriptive, written entirely in uppercase letters, and contain no acronyms. Essential abbreviations must be spelled out at their first occurrence in the text.

5.4 - Abstracts may not contain tables, figures, charts, images, bibliographic references, trademarks, company names, website addresses, or any information identifying the authors or their institutions.

5.5 - Generic names of medications, supplies, methods, and equipment should be used whenever possible.

6 - Information Entered on the Submission Platform

6.1 - Authorship, affiliation, and contact information must be entered exclusively in the designated fields of the submission form and must not appear in the body of the abstract submitted for review.

Submitting Author. Provide a valid email address and mobile phone number. All official communications will be sent to the registered contact information.

Authors. List all authors in the correct order. The first author will be considered the primary contact unless otherwise specified in the system.

Institution. Provide the name of the department, hospital, university, laboratory, or institution, along with the corresponding city.

Keywords. Include three keywords representative of the subject matter, preferably selected from the Health Sciences Descriptors (DeCS) or Medical Subject Headings (MeSH).

Funding and Financial Support. Disclose any funding agency, grant, scholarship, financial support, or other assistance related to the work. If no funding was received, select or declare that no funding was provided.

Conflicts of Interest. Disclose any financial, institutional, or personal relationships that could be perceived as a conflict of interest. If none exist, explicitly declare that there are no conflicts of interest.

7 - Anonymization for Blind Review

7.1 - The abstract text must not contain the first or last names of authors, institutions, hospitals, universities, clinics, laboratories, cities, or any other information that could identify the origin of the work.

7.2 - When institutional information is essential to understanding the methodology, it must be replaced with the word BLINDING, written in uppercase letters.

7.3 - Failure to comply with the anonymization requirements may result in automatic disqualification without scientific merit review.

8 - Abstract Structure

8.1 - Scientific Communication

• Introduction: Brief background on the subject and its relevance.
• Objective: Clearly defined purpose consistent with the methodology.
• Materials and Methods: Description of the study design, sample, criteria, techniques, procedures, and analyses used.
• Results: Objective presentation of the available results. Statements such as "results will be presented at a later date" or equivalent expressions will not be accepted.
• Conclusion: A conclusion consistent with the objective and supported by the results.

8.2 - Case Report

• Introduction: Background and justification for the relevance of the case.
• Case Presentation: Objective description of the relevant clinical, diagnostic, cytopathological, and procedural findings.
• Discussion: Analysis of the findings and their contribution in relation to existing knowledge.
• Conclusion: Summary of the main scientific, diagnostic, or educational contribution of the case.

9 - Ethics, Integrity, and Data Protection

9.1 - Research involving human participants or animals must comply with applicable ethical and legal standards and obtain approval or an exemption from the appropriate ethics committee, whenever required. Supporting documentation may be requested at any time.

9.2 - Case reports must fully protect the patient's identity and privacy. When applicable, authors must retain the relevant informed consent documentation.

9.3 - Fabricated, falsified, plagiarized, improperly manipulated, or unauthorized data will not be accepted.

9.4 - Identification of ethical or research integrity violations may result in rejection, removal from the scientific program, cancellation of awards, and notification of the appropriate institutions.

10 - Use of Artificial Intelligence

10.1 - The use of generative artificial intelligence or AI-assisted technologies must be limited to supporting writing, language editing, and readability, always under human supervision.

10.2 - AI tools may not be listed as authors or co-authors. Authors remain fully responsible for the accuracy, implied references, originality, and content of the submitted work.

10.3 - The use of AI must be disclosed in the designated field on the submission platform, identifying the tool used and its purpose. If no AI tools were used, the corresponding declaration must be provided.

11 - Submission, Corrections, and Withdrawal

11.1 - A submission will be considered complete only after the submit command has been activated and electronic confirmation containing the abstract identification number has been received.

11.2 - Abstracts remaining in draft status after January 31, 2027, will not be forwarded for review.

11.3 - After submission, the content, authorship, and affiliations cannot be changed directly. To correct a paper, the author must withdraw the previous version and submit a new version by January 31, 2027.

11.4 - Withdrawal requests must be submitted by the submitting author, including the title and abstract identification number, via email to bassote@gmail.com.

11.5 - Technical difficulties or questions must be reported via email to bassote@gmail.com before the submission deadline.

12 - Abstract Review Process

12.1 - Abstracts will undergo a blind and independent review by two reviewers appointed according to the paper's subject area.

12.3 - Anyone listed as an author, affiliated with the same institution, or otherwise presenting a conflict of interest may not review the paper. The reviewer must declare the conflict and return the paper for reassignment.

12.4 - The abstract score will be calculated as the average of the scores assigned by the two reviewers. If the difference between the final scores exceeds three points, a third reviewer will evaluate the paper. In calculating the final average, the two closest scores will be considered.

12.5 - If a reviewer declares themselves technically unable to evaluate a paper, it will be reassigned. The Scientific Committees may conduct additional reviews to resolve discrepancies or ensure consistency across subject areas.

13 - Abstract Evaluation Criteria

13.1 - The final abstract score will range from zero to ten points.

13.2 - Papers receiving a final score of 5.0 or higher may be accepted, provided they are recommended by the Scientific Committees and subject to the capacity of the scientific program.

13.3 - Papers receiving a score of 8.0 or higher may be selected for oral presentation and considered for the overall awards, according to their ranking and program availability.

13.4 - Compliance with the word limit, submission category, required structure, anonymization rules, and ethical requirements constitutes a condition of eligibility and may be verified before scientific merit review.

Criterion

Description

Score

Originality

Innovation in the research question, approach, case, or contribution.

0 to 2

Relevance

Scientific, diagnostic, clinical, educational, or social contribution.

0 to 2

Methodological Rigor

Appropriateness of the study design, methods, analysis, and ethical support.

0 to 2

Clarity and Structure

Organization, objectivity, scientific language, and compliance with the required format.

0 to 2

Consistency

Alignment among the objective, methodology, results, and conclusion.

0 to 2

Originality

Description

Innovation in the research question, approach, case, or contribution.

Score

0 to 2

Relevance

Description

Scientific, diagnostic, clinical, educational, or social contribution.

Score

0 to 2

Methodological Rigor

Description

Appropriateness of the study design, methods, analysis, and ethical support.

Score

0 to 2

Clarity and Structure

Description

Organization, objectivity, scientific language, and compliance with the required format.

Score

0 to 2

Consistency

Description

Alignment among the objective, methodology, results, and conclusion.

Score

0 to 2

14 - Announcement of Abstract Evaluation Results

14.1 - Results will be announced on March 5, 2027, through the restricted-access area, by email, and/or on the Congress's official website.

14.2 - The notification will indicate the status of the paper and, when available, the presentation format, date, time, and location.

14.3 - Decisions made by the Scientific Committees are technical, collective, and final. Appeals regarding scores or rankings will not be accepted, without prejudice to the correction of documented clerical errors.

15 - Oral Presentations

15.1 - Selected papers will be presented during a dedicated session, with seven minutes allotted for the presentation and three minutes for questions.

15.2 - Presentations must use the official Congress template in 16:9 widescreen format and comply with the submission deadline and procedures communicated to the authors.

15.3 - The presentation must be delivered by the designated author who is registered for the Congress. Any substitutions will require prior authorization from the Scientific Committees.

16 - Poster Presentations

16.1 - Selected papers must use the official Congress template. The final format, dimensions or digital specifications, and submission instructions will be announced on March 5, 2027.

16.2 - The presenting author must remain available during the designated evaluation and discussion period. Unjustified absence may result in exclusion from award consideration.

16.3 - Posters must present clear, concise, and readable content consistent with the approved abstract. Substantial changes to the study after acceptance will not be permitted.

17 - Presentation Evaluation and Final Ranking

17.1 - Presentations will be evaluated during the Congress by an appointed Judging Committee. No reviewer with a conflict of interest or disqualifying circumstances may participate.

17.2 - The final ranking for cash awards will consider papers selected for oral presentation and will be determined by the score assigned to the presentation at the Congress.

17.3 - Each presentation will receive a score ranging from zero to ten points, calculated as the average of the scores assigned by the members of the Judging Committee.

17.4 - In the event of a tie, the following criteria will be applied successively: higher score in scientific quality; higher score in methodology; higher score in relevance; higher abstract score; and a reasoned collective decision by the Judging Committee.

Oral Presentation Evaluation Criteria

Criterion

Description

Score

Scientific Quality

Consistency, originality, and command of the subject matter.

0 to 2

Methodology

Appropriateness and explanation of the methods and analysis.

0 to 2

Relevance

Scientific, diagnostic, clinical, educational, or social impact.

0 to 2

Presentation Clarity

Organization, communication, visual quality, and objectivity.

0 to 2

Time Management and Q&A

Compliance with the allotted time and quality of responses.

0 to 2

Scientific Quality

Description

Consistency, originality, and command of the subject matter.

Score

0 to 2

Methodology

Description

Appropriateness and explanation of the methods and analysis.

Score

0 to 2

Relevance

Description

Scientific, diagnostic, clinical, educational, or social impact.

Score

0 to 2

Presentation Clarity

Description

Organization, communication, visual quality, and objectivity.

Score

0 to 2

Time Management and Q&A

Description

Compliance with the allotted time and quality of responses.

Score

0 to 2

Poster Presentation Evaluation Criteria

Criterion

Description

Score

Scientific Quality

Consistency, originality, and contribution of the work.

0 to 2

Methodology

Appropriateness of the methods, data, and analysis.

0 to 2

Visual Organization

Readability, hierarchy, balance, and appropriate use of visual elements.

0 to 2

Clarity and Conciseness

Objectivity and consistency among the objective, results, and conclusion.

0 to 2

Presentation and Q&A

Command of the subject matter and quality of the presenter's responses.

0 to 2

Scientific Quality

Description

Consistency, originality, and contribution of the work.

Score

0 to 2

Methodology

Description

Appropriateness of the methods, data, and analysis.

Score

0 to 2

Visual Organization

Description

Readability, hierarchy, balance, and appropriate use of visual elements.

Score

0 to 2

Clarity and Conciseness

Description

Objectivity and consistency among the objective, results, and conclusion.

Score

0 to 2

Presentation and Q&A

Description

Command of the subject matter and quality of the presenter’s responses.

Score

0 to 2

18 - Awards

18.1 - First, second, and third-place awards will be granted to the highest-ranked papers in the final evaluation of oral presentations.

18.2 - The Best Poster Award will be granted to the paper receiving the highest score in the poster evaluation.

18.3 - If the award consists of complimentary registration for SLAC 2029, it will be personal, issued in the recipient's name, and non-transferable. It will cover the registration fee only and will not include transportation, accommodation, meals, or any other expenses.

18.4 - To receive an award, the presenting author must have delivered the presentation and be present at the closing ceremony, unless an explanation has been submitted in advance and accepted by the Scientific Committees.

18.5 - Honorable Mentions may be granted at the discretion of the Judging Committee, without any monetary award or additional benefit.

19 - Publication and Rights

19.1 - By submitting an abstract, authors authorize its publication in the Congress proceedings, on the website, on the submission platform, and in the Congress's scientific materials, including the names and affiliations provided during registration.

19.2 - Publication does not transfer intellectual property ownership of the work, which remains with its authors, nor does it relieve them of responsibility for its content.

20 - Final Provisions

Failure to comply with these Regulations may result in rejection of the abstract, removal from the scientific program, or cancellation of an award, depending on the severity of the violation and when it is identified.

Any matters not addressed in these Regulations will be decided by the Scientific Committees and the Organizing Committee of the SLAC Congress and IAC Tutorial 2027.

These Regulations shall take effect on the date of their publication through the Congress's official communication channels.